Hydrogen Research Study
← Back to Research Library
Preclinical animal evidenceAnimal studyinhaled hydrogen gas

Magnesium silicate nanosheets enable sustained hydrogen release to attenuate secondary brain injury following intracerebral hemorrhage.

Chang-Sheng Ma, Bo Han, Jia-Ru Guo, Jin-Fen Guo, Chang-Ku Shi, Yu-Xi Liu, Wen-Jing Yi, Li-Ying Zhang, Ai-Jun Deng, Ying-Shuai Wang, Mao-Tao He · Journal of translational medicine · 2026

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Stroke and Brain Injury
Evidence type Preclinical animal evidence
Publication type Animal study
Hydrogen method inhaled hydrogen gas

H2HUBB TAKEAWAY

In mice, however, the reduction was significantly greater in the MGNs-treated group compared to the group treated with 3% H₂, indicating that MGNs have a superior therapeutic effect. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

What the Findings Mean

H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in mice. However, the reduction was significantly greater in the MGNs-treated group compared to the group treated with 3% H₂, indicating that MGNs have a superior therapeutic effect.

What the Researchers Studied

The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.

What Effects Did Molecular Hydrogen Have?

Source-reported hydrogen concentration: 3% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 3% source-reported H₂ gas concentration. However, the reduction was significantly greater in the MGNs-treated group compared to the group treated with 3% H₂, indicating that MGNs have a superior therapeutic effect. The authors concluded that mGNs represent a safe and effective hydrogen-releasing nanoplatform that alleviates secondary brain injury after ICH, highlighting their potential for translational neuroprotective therapy. 8 Schematic illustration of the preparation, hydrogen release, and neuroprotective mechanism of MGNs in ICH MGNs were synthesized from Mg₂Si by ball milling followed by exfoliation.

Why These Findings Matter

These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.

How Strong Is This Evidence?

This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.

Technical Study Details

H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 3% source-reported H₂ gas concentration.

Limitations and Safety

Reported limitations: Molecular hydrogen (H₂) exhibits potent neuroprotective effects; however, its clinical translation is limited by poor bioavailability and the lack of sustained delivery strategies.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.